Loading organizations...
§ Private Profile · San Diego, CA, USA
Biotechnology company developing antibody-drug conjugate (ADC) therapeutics for oncology and life-threatening diseases.
Adcentrx Therapeutics is a clinical-stage biotechnology company developing next-generation antibody-drug conjugate therapeutics for the treatment of solid tumors, based in San Diego, California, United States. The enterprise currently operates with an estimated 10 to 50 employees and maintains additional research and development facilities located in Shanghai, China. Transitioning from discovery into a clinical-stage entity, the firm recently dosed the first patient in a Phase 1 clinical trial for its lead candidate, ADRX-0706, following official FDA clearance of its investigational new drug application. To support these ongoing clinical development efforts, Adcentrx has secured over $88 million in total venture financing to date, including a $50 million Series A and a subsequent $38 million Series A+ round backed by institutional investors Eight Roads Ventures, F-Prime Capital, CBC Group, and Zoo Capital. The company was founded in 2021 by Dr. Hui Li.
Adcentrx Therapeutics has raised $51.0M across 2 funding rounds.
Adcentrx Therapeutics has raised $51.0M in total across 2 funding rounds.
Adcentrx Therapeutics has raised $51.0M in total across 2 funding rounds.
Adcentrx Therapeutics's investors include Partners Investment, Quan Capital, Tao Huang, Jeffrey Jonas, Delta Capital, F-Prime Capital, Trinity Innovation Fund.
Adcentrx Therapeutics has raised $51.0M across 2 funding rounds. Most recently, it raised $13.0M Series A Extension in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 6, 2023 | $13M Series A Plus | Partners Investment, Quan Capital, TAO Huang | Jeffrey Jonas | Announced |
| Apr 25, 2023 | $38M Series A | TAO Huang | Jeffrey Jonas, Delta Capital, F Prime Capital, Trinity Innovation Fund | Announced |